Literature DB >> 9581703

Determinants of outcome of compensated hepatitis C virus-related cirrhosis.

L Serfaty1, H Aumaître, O Chazouillères, A M Bonnand, O Rosmorduc, R E Poupon, R Poupon.   

Abstract

The aim of this study was to assess the incidence of decompensation (ascites, jaundice, variceal bleeding, and encephalopathy), hepatocellular carcinoma (HCC) and death or liver transplantation in patients with compensated hepatitis C virus (HCV)-related cirrhosis, taking into account the viral genotype and interferon (IFN) therapy. Between 1989 and 1994, 668 patients with no clinical evidence of decompensation were referred to our department for liver biopsy because of positivity for anti-HCV antibodies and elevated aminotransferase activity; 103 of these patients had cirrhosis. The median follow-up was 40 months. Fifty-nine patients were treated with IFN for a mean duration of 11+/-6 months; 3 (5%) had a prolonged biochemical and virological response. Baseline characteristics of IFN-treated and untreated patients were not significantly different. HCV genotypes (InnoLiPa) were predominantly 1b (48%) and 3a (20%). During follow-up, complications of cirrhosis occurred in 26 patients, HCC in 11 patients, and decompensation not related to HCC in 19 patients. Sixteen patients died, 94% of liver disease. Three patients were transplanted for liver failure. The 4-year risk of HCC was 11.5% (annual incidence 3.3%) and that of decompensation was 20%. Survival probability was 96% and 84% at 2 and 4 years, respectively. In multivariate analysis, the absence of IFN therapy was the only independent factor predictive both for HCC and decompensation. A low albumin level at entry and the absence of IFN therapy were the two independent factors predictive of death or liver transplantation. Probability of survival at 2 and 4 years was significantly different between IFN-treated and untreated patients (respectively 97% and 92% vs 95% and 63%, P < .0001). In conclusion, in patients with compensated HCV-related cirrhosis: 1) complications of cirrhosis are frequent, whatever the viral genotype; and 2) the severity of cirrhosis and the absence of IFN therapy are independently predictive of bad outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9581703     DOI: 10.1002/hep.510270535

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  62 in total

Review 1.  Hepatitis C and liver transplantation.

Authors:  M Berenguer; T L Wright
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

2.  Interferon therapy reduces the risk for hepatocellular carcinoma.

Authors:  J L Brown
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

3.  Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Authors:  A Gramenzi; P Andreone; S Fiorino; C Cammà; M Giunta; D Magalotti; C Cursaro; C Calabrese; V Arienti; C Rossi; G Di Febo; M Zoli; A Craxì; G Gasbarrini; M Bernardi
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

4.  Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.

Authors:  Mazen Noureddin; Marc G Ghany
Journal:  Am J Gastroenterol       Date:  2010-10       Impact factor: 10.864

Review 5.  Treatment of chronic hepatitis C in nonresponders to previous therapy.

Authors:  Todd E Dantzler; Eric J Lawitz
Journal:  Curr Gastroenterol Rep       Date:  2003-02

6.  Hepatitis C virus replication and potential targets for direct-acting agents.

Authors:  Jacqueline G O'Leary; Gary L Davis
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

7.  Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.

Authors:  Yasuto Takeuchi; Fusao Ikeda; Toshiya Osawa; Yasuyuki Araki; Kouichi Takaguchi; Youichi Morimoto; Noriaki Hashimoto; Kousaku Sakaguchi; Tatsuro Sakata; Masaharu Ando; Yasuhiro Makino; Shuji Matsumura; Hiroki Takayama; Hiroyuki Seki; Shintarou Nanba; Yuki Moritou; Tetsuya Yasunaka; Hideki Ohnishi; Akinobu Takaki; Kazuhiro Nouso; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  World J Hepatol       Date:  2015-09-08

8.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

9.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

10.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.